A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Autor: Alicia Rodriguez-Gabin, Leleesha Samaraweera, Hayley M. McDaid, Alfred Adomako

Publikováno v: Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)

Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::badc9ac646a1255ca805305f6fd0fc76
https://doi.org/10.1038/s41598-017-01964-1

In Vivo Invasion of Head and Neck Squamous Cell Carcinoma Cells Does Not Require Macrophages

Autor: Jeffrey E. Segall, Michael B. Prystowsky, Nico van Rooijen, Alfred Adomako, Tatiana Smirnova, Joseph Locker

Publikováno v: The American Journal of Pathology, 178(6), 2857-2865. Elsevier Inc.
Smirnova, T, Adomako, A, Locker, J, van Rooijen, N, Prystowsky, M B & Segall, J E 2011, ' In Vivo Invasion of Head and Neck Squamous Cell Carcinoma Cells Does Not Require Macrophages ', The American Journal of Pathology, vol. 178, no. 6, pp. 2857-2865 . https://doi.org/10.1016/j.ajpath.2011.02.030

Invasion of tumor cells into the local stroma is an important component in cancer progression. Here we report studies of the in vivo invasion of head and neck squamous cell carcinoma (HNSCC) cells in response to applied gradients of a growth factor [

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e5e1970f51f744ce6a5b383f35863af
https://europepmc.org/articles/PMC3124357/

Abstract SY17-02: Mechanisms driving dormancy of disseminated tumor cells

Autor: Julio A. Aguirre-Ghiso, Yeriel Estrada, Maria Soledad Sosa, Alvaro Avivar-Valderas, Esther Ekpin, Kathryn Harper, Paloma Bragado, Alfred Adomako

Publikováno v: Cancer Research. 72:SY17-02

The vast majority of cancer related deaths are due to metastasis. However, our understanding of this process is limited. This is clearer when we consider that these lesions can develop years or decades after successful primary tumor treatment. These

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9d7e40d5ae942bd52e3fa08395b1314
https://doi.org/10.1158/1538-7445.am2012-sy17-02

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

Autor: Ajai Chari, Julio A. Aguirre-Ghiso, Noa Biran, Adrienne W. Paton, Denis M. Schewe, Alfred Adomako, Kateri A. Moore, Veronica Calvo, Keren Osman, James C. Paton

Publikováno v: BMC Cancer

Background The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal markers to identify these cells and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea84495bc26814665d8aae09e83ee540